厄贝沙坦氢氯噻嗪复方制剂治疗原发性高血压有效性及安全性的Meta分析

J4 ›› 2011, Vol. 37 ›› Issue (3): 517-522.

厄贝沙坦氢氯噻嗪复方制剂治疗原发性高血压有效性及安全性的Meta分析

吴海帝|徐国良|秦玲

吉林大学第一医院二部心内科|吉林长春 130031

收稿日期:2010-12-06 出版日期:2011-05-28 发布日期:2011-05-28
通讯作者: 徐国良（Tel:0431-84808227，E-mail:glxublog@sohu.com）; 秦玲（Tel:0431-84808229，E-mail:qinling@medmail.com.cn） E-mail:glxublog@sohu.com;qinling@medmail.com.cn
作者简介:吴海帝（1987-）|女|黑龙江省佳木斯市人|在读医学硕士|主要从事高血压及冠心病的基础、临床及循证医学的研究。
基金资助:
吉林省科技厅科研基金资助课题( 200905138)

Meta-analysis on effectiveness and safety of irbesarten/hydrochlorothiazide combination therapy in treatment of 
essential hypertension

WU Hai-di|XU Guo-Liang|QIN Ling

Department of Cardiology,Second Part of First Hospital,Jilin University,Changchun 130031,China

Received:2010-12-06 Online:2011-05-28 Published:2011-05-28

摘要/Abstract

摘要：

目的：利用Meta分析方法探讨厄贝沙坦氢氯噻嗪复方制剂治疗原发性高血压的有效性及安全性，为其临床应用提供依据。方法：计算机检索Cochrane图书馆临床对照试验资料库(2010年第03期)、Ovid-medline全文数据库(1966－2010.09)、PubMed数据库（1948－2010.09）、EMBASE数据库(1966－2010.09)、中国学术文献总库(CNKI)(1979－2010.09)、万方数字化期刊库（1981－2010.09）及维普数据库(VIP) (1989－2010.09)，手工检索相关文献，按纳入与排除标准选择试验、评价质量，提取资料，并用RevMan 4.2软件对数据进行Meta分析。结果：共初检出516篇文献，经筛选最终纳入5篇6项关于厄贝沙坦氢氯噻嗪治疗原发性高血压的随机双盲对照研究。有效性：χ²=7.50，df=5，P=0.19，Z=7.23（P<0.00001），合并OR=2.26，95％CI ［1.81，2.82］；安全性：χ²=7.82，df=5，P=0.17，Z=1.11（P=0.27），合并OR=0.87，95％CI ［0.68，1.11］。结论：厄贝沙坦氢氯噻嗪复方制剂治疗原发性高血压与对照组比较具有较高的有效性及相似的安全性。

关键词: 厄贝沙坦；氢氯噻嗪；原发性高血压；Meta分析

Abstract:

Objective To approach the effectiveness and safety of irbesarten/hydrochlorothiazide combination therapy in treating essential hypertension with Meta-analysis and provide basis for their application in clinic. Methods Computer
search was performed using the Cochrane Central Register of Controlled Trial MBA SE(1966 to September 2010),CNKI(1979 to September 2010),WanFang(1981-2010.09）,VIP（1989-2010.09），the randomized controlled trials (RCTs) were collected,then the retrieved studies according to predefined inclusion and exclusion criteria were screened,the quality of included studies was evaluated and RevMan 4.2 software was used for Meta analysis.Results A total of 516 articles were found and 5 of which were finally included. Effectiveness:χ2=7.50，df=5，P=0.19，Z=7.23（P<0.00001），OR=2.26，95％CI［1.81，2.82］；Safety:χ2=7.82
，df=5，P=0.17，Z=1.11（P=0.27），OR=0.87，95％CI［0.68，1.11］. Conclusion Irbesarten/hydrochlorothiazide combination therapy is more effective than control group in treating essential hypertension and there is no significant difference in safety between them.

Key words: irbesarten, hydrochlorothiazide；essential hypertension；Mata-analysis

中图分类号:

R544.1

吴海帝|徐国良|秦玲. 厄贝沙坦氢氯噻嗪复方制剂治疗原发性高血压有效性及安全性的Meta分析[J]. J4, 2011, 37(3): 517-522.

WU Hai-di|XU Guo-Liang|QIN Ling. Meta-analysis on effectiveness and safety of irbesarten/hydrochlorothiazide combination therapy in treatment of 
essential hypertension[J]. J4, 2011, 37(3): 517-522.